Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Invivyd, Inc.ADGI · Entity 721 | Director | August 05, 2021 | August 09, 2021 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director | June 02, 2021 | June 02, 2021 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director · PRESIDENT AND CEO | December 31, 2025 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Invivyd, Inc.
Report date August 05, 2021 · Filed August 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-08-04 | Direct | 35,593 |
Reported balance
After 2021-08-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-05 · Grant · Acquired 35,593 · Balance 35,593 F1: One third (1/3) of the option shall vest on August 5, 2022, and thereafter, the remainder of the option shall vest in 24 equal monthly installments on the 5th day of each month, subject to the Reporting Person's continuous service on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One third (1/3) of the option shall vest on August 5, 2022, and thereafter, the remainder of the option shall vest in 24 equal monthly installments on the 5th day of each month, subject to the Reporting Person's continuous service on each vesting date.
X4 Pharmaceuticals, Inc
Report date June 02, 2021 · Filed June 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.50 · Expires 2031-06-02 | Direct | 6,000 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 6,000 · Balance 6,000 F1: 8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date.
Xilio Therapeutics, Inc.
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 325,422 |
Reported balance
After 2026-01-01 transaction · row 1
1 source rowRow 1 · 2026-01-01 · Exercise / conversion · Acquired 44,250 · Balance 325,422 F1: Restricted stock units ("RSUs") convert to stock on a one-for-one basis. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2035-10-07 | Direct | 1,500,258 |
Reported balance
After 2025-12-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-31 · Grant · Acquired 1,500,258 · Balance 1,500,258 F2: On October 8, 2025, the Board of Directors (the "Board") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as "Tranche 3 Options" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met. F3: The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025. F4: This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 88,500 |
Reported balance
After 2026-01-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-01 · Exercise / conversion · Disposed 44,250 · Balance 88,500 F1: Restricted stock units ("RSUs") convert to stock on a one-for-one basis. F5: These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert to stock on a one-for-one basis.
F2: On October 8, 2025, the Board of Directors (the "Board") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as "Tranche 3 Options" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met.
F3: The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025.
F4: This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date.
F5: These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2026 Filed Jan 5, 2026 16:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Exercise / conversionRestricted Stock Units · Derivative | 44,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-002512 · ownership.xml · derivative · entry 3 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,500 Underlying: Common Stock · 44,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert to stock on a one-for-one basis. F5 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025. F5 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and vest in four equal annual installments beginning on January 1, 2025. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 16:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Exercise / conversionCommon Stock | 44,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-002512 · ownership.xml · nonDerivative · entry 1 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert to stock on a one-for-one basis. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 16:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 1,500,258 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001193125-26-002512 · ownership.xml · derivative · entry 2 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500,258 Underlying: Common Stock · 1,500,258 shares Expires 2035-10-07 F2 · date: On October 8, 2025, the Board of Directors (the "Board") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as "Tranche 3 Options" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. On December 31, 2025, the performance criteria for a portion of the Tranche 3 Options was met. F3 · shares: The portion of Tranche 3 Options that achieved the vesting condition is equal to the percentage of the Series B Warrants exercised and/or cancelled due to the receipt by Xilio Therapeutics, Inc. of Non-Dilutive Capital (as defined in the Series B Warrants) by December 31, 2025. F4 · derivative.exercise_date: This option vests in three (3) equal annual installments over the three-year period beginning on December 31, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 700,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 17 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2033-08-15 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Disposition to issuerStock Option (right to buy) · Derivative | 700,000 | Not disclosed Strike: $2.79 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 16 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 700,000 shares Expires 2033-08-15 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 350,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 15 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-12-31 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F7 · derivative.exercise_date: This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Disposition to issuerStock Option (right to buy) · Derivative | 350,000 | Not disclosed Strike: $2.69 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 14 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 350,000 shares Expires 2032-12-31 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F7 · derivative.exercise_date: This option was granted on January 1, 2023. The shares underlying the option began vesting on February 1, 2023 and continue to vest in equal monthly installments thereafter through January 1, 2027. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 13 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-02-21 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F6 · derivative.exercise_date: This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Disposition to issuerStock Option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $12.66 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 12 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2032-02-21 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F6 · derivative.exercise_date: This option was granted on February 22, 2022. The shares underlying the option began vesting on March 1, 2022 and continue to vest in equal monthly installments thereafter through February 1, 2026. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 11 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-21 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F5 · derivative.exercise_date: This option was granted on December 22, 2021. The shares underlying the option began vesting on January 1, 2022 and continue to vest in equal monthly installments thereafter through December 1, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Disposition to issuerStock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $13.83 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 10 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2031-12-21 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F5 · derivative.exercise_date: This option was granted on December 22, 2021. The shares underlying the option began vesting on January 1, 2022 and continue to vest in equal monthly installments thereafter through December 1, 2025. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 50,041 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 9 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,041 Underlying: Common Stock · 50,041 shares Expires 2031-10-20 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Disposition to issuerStock Option (right to buy) · Derivative | 50,041 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 8 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,041 shares Expires 2031-10-20 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 135,134 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 7 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,134 Underlying: Common Stock · 135,134 shares Expires 2031-08-22 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Disposition to issuerStock Option (right to buy) · Derivative | 135,134 | Not disclosed Strike: $11.69 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 6 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 135,134 shares Expires 2031-08-22 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 473,334 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 5 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,334 Underlying: Common Stock · 473,334 shares Expires 2031-03-10 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Disposition to issuerStock Option (right to buy) · Derivative | 473,334 | Not disclosed Strike: $5.89 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 4 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 473,334 shares Expires 2031-03-10 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 239,703 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 3 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,703 Underlying: Common Stock · 239,703 shares Expires 2030-07-22 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Disposition to issuerStock Option (right to buy) · Derivative | 239,703 | Not disclosed Strike: $5.51 | Not disclosed |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 2 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 239,703 shares Expires 2030-07-22 F4 · price: The transactions reported herein reflect a one-time option repricing, effective on November 21, 2025, which reduced the exercise price of each repriced option to $1.50 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case, the original exercise price must be paid (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting and expiration, remain in full force and effect. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 21, 2025 Filed Nov 25, 2025 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 2,075,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001193125-25-297203 · ownership.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,075,000 Underlying: Common Stock · 2,075,000 shares Expires 2035-10-07 F1 · date: On October 8, 2025, the Board of Directors (the "Board") approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan"), subject to stockholder approval of the adoption of the 2025 Plan. On October 8, 2025, the Compensation Committee of the Board granted these options (referred to as "Tranche 1 Options" in the 2025 Plan) to the Reporting Person, subject to stockholder approval of the adoption of the 2025 Plan. The stockholders approved the adoption of the 2025 Plan on November 21, 2025. F2 · derivative.exercise_date: The options vest in 36 equal monthly installments over the three-year period beginning on December 21, 2025, subject to the Reporting Person's continued service to the registrant through each applicable vesting date. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 16:56 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | PurchaseCommon Stock | 36,289 | $0.68 | $24,680.15 |
DisclosureSEC source: 0001415889-25-017704 · form4-06182025_080644.xml · nonDerivative · entry 1 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,172 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6551 to $0.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 16:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 190,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001415889-25-010805 · form4-04162025_040405.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2035-04-14 F1 · derivative.exercise_date: The option was granted on April 15, 2025 and will vest in equal monthly installments beginning on May 1, 2025 through April 1, 2029. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 16:15 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 638,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001415889-25-000405 · form4-01032025_040111.xml · derivative · entry 3 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 638,000 Underlying: Common Stock · 638,000 shares Expires 2035-12-31 F3 · derivative.exercise_date: The option was granted on January 1, 2025 and will vest in 48 equal monthly installments beginning on February 1, 2025 and continuing through January 1, 2029. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 16:15 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Exercise / conversionRestricted Stock Units · Derivative | 44,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000405 · form4-01032025_040111.xml · derivative · entry 2 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,750 Underlying: Common Stock · 44,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis F2 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. F2 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 16:15 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | Exercise / conversionCommon Stock | 44,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000405 · form4-01032025_040111.xml · nonDerivative · entry 1 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs) convert to stock on a one-for-one basis Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:10 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 474,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0001415889-24-012149 · form4-05032024_040501.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,000 Underlying: Common Stock · 474,000 shares Expires 2034-04-30 F1 · derivative.exercise_date: The option award was granted on May 1, 2024 and shall vest on June 1, 2024 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until May 1, 2028. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 16:15 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantRestricted Stock Units · Derivative | 177,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000276 · form4-01032024_040101.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,000 Underlying: Common Stock · 177,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. F2 · derivative.expiration_date: These RSUs were granted on January 1, 2024 and will vest in four equal annual installments beginning on January 1, 2025 and continuing through January 1, 2028. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:45 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 700,000 | $0.00 Strike: $2.79 | $0.00 |
DisclosureSEC source: 0001415889-23-012418 · form4-08182023_080801.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2033-08-15 F1 · derivative.exercise_date: The option award was granted on August 16, 2023 and shall vest with respect to 1/3 of the shares of common stock underlying the stock option on the first anniversary of the grant date and with respect to the remaining 2/3 of the shares of common stock underlying the stock option on the second anniversary of the grant date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 16:14 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001415889-23-000291 · form4-01042023_090151.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2032-12-31 F1 · derivative.exercise_date: The option award was granted on January 1, 2023 and shall vest on February 1, 2023 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until January 1, 2027. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 17:30 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $12.66 | $0.00 |
DisclosureSEC source: 0001415889-22-001791 · form4-02242022_050201.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · CEO AND PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2032-02-21 F1 · derivative.exercise_date: The option award was granted on February 22, 2022 and shall vest on March 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until February 1, 2026. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 19:06 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $13.83 | $0.00 |
DisclosureSEC source: 0001415889-21-006215 · form4-12232021_041229.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · CEO AND PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-21 F1 · derivative.exercise_date: The option award was granted on December 22, 2021 and shall vest on January 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until December 1, 2026. Read SEC document |
| December 22, 2021 Filed Jan 4, 2022 17:32 UTC Amendment | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $13.83 | $0.00 |
DisclosureSEC source: 0001415889-22-000247 · form4a-01042022_020119.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · CEO AND PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-12-21 F1 · derivative.exercise_date: The option award was granted on December 22, 2021 and shall vest on January 1, 2022 with respect to 1/48th of the shares of common stock underlying the stock option and continue to vest in equal monthly installments thereafter until December 1, 2025. F2 · derivative.exercise_date: On December 23, 2021, the reporting person filed a Form 4 that inadvertently reported that the stock option shall continue to vest until December 1, 2026. This amendment is being filed solely to correct such date to December 1, 2025, as set forth in footnote 1. Read SEC document |
| October 21, 2021 Filed Oct 25, 2021 17:18 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 50,041 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-21-129572 · tm2130646-23_4seq1.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · CEO and President · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,041 Underlying: Common Stock · 50,041 shares Expires 2031-10-20 F1 · derivative.exercise_date: The option award was granted on October 21, 2021 and shall begin to vest on November 1, 2021 and continue to vest in equal monthly installments thereafter until October 1, 2025. Read SEC document |
| August 05, 2021 Filed Aug 9, 2021 19:55 UTC | Invivyd, Inc. ADGI · Entity 721 | GrantStock Option (Right to Buy) · Derivative | 35,593 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-050489 · doc4.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,593 Underlying: Common Stock · 35,593 shares Expires 2031-08-04 F1 · derivative.exercise_date: One third (1/3) of the option shall vest on August 5, 2022, and thereafter, the remainder of the option shall vest in 24 equal monthly installments on the 5th day of each month, subject to the Reporting Person's continuous service on each vesting date. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 20:57 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 6,000 | $9.50 Strike: $9.50 | $57,000.00 |
DisclosureSEC source: 0001628280-21-011534 · wf-form4_162266743993002.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 12:31 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 3,427 | $0.00 Strike: $8.69 | $0.00 |
DisclosureSEC source: 0001628280-20-009238 · wf-form4_159187868380574.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,427 Underlying: Common Stock · 3,427 shares Expires 2030-06-09 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 10, 2020, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 20:19 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 3,427 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0000899243-19-017423 · doc4.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,427 Underlying: Common Stock · 3,427 shares Expires 2029-06-17 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 17, 2019, with the remainder vesting in equal monthly installments of 8.3333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant), subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 21:35 UTC | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantStock option (right to buy) · Derivative | 160,000 | $0.00 Strike: $17.34 | $0.00 |
DisclosureSEC source: 0001209191-18-018513 · doc4.xml · derivative · entry 1 Russo Rene · CIK 0001722066 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2028-03-06 F1 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the fourth anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.